The market knows what fair value is. No doubt they were involved in the raising, and desperately want to dump their shares. Nice try.
The truth is that PI-88 has now been confirmed as a much more narrowly focussed drug, and failed to meet any endpoints in a cancer trial of the most closely-related tissue type. The impact on potential revenue is devastating, and there is no way of sugar-coating it. PI-88 was priced as a drug for multiple conditions, and now it's been demonstrated as merely a specialty drug, with a small target market.
Good luck partnering a drug without broad efficacy. It just doesn't happen.
All hope now rests with their next-generation compound. Price target $1.50.
analysts do not have a clue
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.64M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 43.5¢ | $53.67K | 123.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 743246 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 125621 | 4 |
View Market Depth
| Last trade - 12.57pm 20/06/2024 (20 minute delay) ? |
| PGL (ASX) Chart |